Posts in tag

biologics


The emergence of biologic therapies represents one of the most significant advances in COPD management in more than 20 years. Understanding which patients may benefit, how these medicines work, and …

Biosimilar switching and even administration will be significant parts of full scope of practice – but pharmacists need confidence, says a sector leader Pharmacy stakeholders went to Parliament House, Canberra …

Biosimilars and the pharmacist’s role in their supply remains controversial, writes Carlene McMaugh Biological pharmaceutical products have been a part of the landscape of therapeutics for a number of years …

Pharmacists’ authority to use their expertise to substitute one medicine for another should also apply to biological medicines, says FIP The International Pharmaceutical Federation has published a revised Statement of …

In the latest in our series based on 2017 UTS Pharmacy Barometer results, John Montgomery looks at how pharmacists view the riding tide of biosimilar medicines  There’s little doubt biosimilar …

The ACTU has attacked the government over the revived TPP, claiming it would drive up drug prices ACTU president Ged Kearney says that the Trans Pacific Partnership, which is set …

Time for costly medicine monopolies to go from TPP trade talks Belinda Townsend, Australian National University; Deborah Gleeson, La Trobe University; Hazel Moir, Australian National University; Joel Lexchin, University of …

Guild Learning and Development is partnering with AbbVie Pty Ltd in an online course titled “Understanding biologic medicines” AbbVie’s General Manager Kirsten O’Doherty says the course plays an important role …

Minister confirms a range of initiatives to boost pharmacy’s primary care role The Federal government is moving to give certainty to community pharmacy over location rules, Health Minister Greg Hunt …

The asthma medicines market is set to grow with incoming biologics and climbing disease rates, say market researchers The asthma therapeutics market in the Asia-Pacific region is expected to grow from …

While they present a cost-saving opportunity, safety data on biosimilars is still limited, warns IBD specialist There is an absence of data on adverse reactions or potential development of anti-drug …

The way a biosimilar is named may affect whether a pharmacist is willing to substitute it for a brand name biologic, a new study has found. The study, published in …